Abbott Clears US Antitrust Hurdle for Ibis Buy | GenomeWeb
NEW YORK (GenomeWeb News) – Abbott today said that it has received clearance from US antitrust regulators to proceed with the acquisition of Isis Pharmaceuticals’ molecular diagnostics subsidiary Ibis Biosciences.
 
The clearance comes less than a week after Abbott said that it had exercised its option to acquire the remaining 81.4 percent stake of Ibis that it didn’t already own for $175 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.